NCR as a biomarker for nutritional status and inflammation in predicting outcomes in patients with cancer cachexia: a prospective, multicenter study

Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia. This prospect...

Full description

Saved in:
Bibliographic Details
Published inBMC cancer Vol. 25; no. 1; pp. 539 - 11
Main Authors Li, Xiangrui, Deng, Li, Xie, Hailun, Li, Shuqun, Zhao, Hong, Liu, Tong, Liu, Xiaoyue, Lin, Shiqi, Liu, ChengAn, Shi, Han-Ping
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 25.03.2025
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia. This prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics. Among the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life. The NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia.
AbstractList Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia.BACKGROUNDSystemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia.This prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics.METHODSThis prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics.Among the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life.RESULTSAmong the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life.The NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia.CONCLUSIONThe NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia.
Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia. This prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics. Among the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life. The NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia.
BackgroundSystemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia.MethodsThis prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics.ResultsAmong the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life.ConclusionThe NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia.
Background Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia. Methods This prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics. Results Among the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life. Conclusion The NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia. Keywords: NCR, Systemic inflammation, Malnutrition, Cancer cachexia, Overall survival
Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia. This prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics. Among the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life. The NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia.
Abstract Background Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the prognostic value of a new nutritional and inflammatory index, Prognostic Nutritional CRP Ratio (NCR), in patients with cancer cachexia. Methods This prospective multicenter study analyzed 3,447 patients diagnosed with cancer cachexia across over 40 clinical centers in China, from June 2012 to December 2023. The NCR was calculated as BMI × albumin / CRP. The Cox proportional hazards regression model was utilized to analyze hazard ratios (HRs) for all-cause mortality. The relationship between NCR and all-cause mortality was assessed using restricted cubic spline modeling. The optimal cutoff value for NCR was determined through maximally selected rank statistics. Results Among the 3,447 individuals diagnosed with cancer cachexia in our study, 2,296 (66.6%) were men, and 1,151 (33.4%) were women. With a median follow-up duration of 45.33 months, the mean age of the participants was 63.8 ± 11.4 years. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. We observed that lower NCR levels were prevalent among cachexia patients across a spectrum of cancer types, including lung, colorectal, liver, esophageal, breast, ovarian, and cervical cancers. This correlation held true across diverse patient subgroups, delineated by gender, age, smoking status, BMI, TNM stage, and tumor types, underscoring the broad applicability of NCR as a prognostic marker. Moreover, our findings highlighted that cancer cachexia patients with higher NCR levels experienced a significantly improved quality of life. Conclusion The NCR, indicative of nutritional status and inflammation, is associated with reduced all-cause mortality and could be a valuable prognostic marker for patients with cancer cachexia.
ArticleNumber 539
Audience Academic
Author Deng, Li
Xie, Hailun
Liu, Tong
Shi, Han-Ping
Li, Shuqun
Lin, Shiqi
Liu, ChengAn
Li, Xiangrui
Liu, Xiaoyue
Zhao, Hong
Author_xml – sequence: 1
  givenname: Xiangrui
  surname: Li
  fullname: Li, Xiangrui
– sequence: 2
  givenname: Li
  surname: Deng
  fullname: Deng, Li
– sequence: 3
  givenname: Hailun
  surname: Xie
  fullname: Xie, Hailun
– sequence: 4
  givenname: Shuqun
  surname: Li
  fullname: Li, Shuqun
– sequence: 5
  givenname: Hong
  surname: Zhao
  fullname: Zhao, Hong
– sequence: 6
  givenname: Tong
  surname: Liu
  fullname: Liu, Tong
– sequence: 7
  givenname: Xiaoyue
  surname: Liu
  fullname: Liu, Xiaoyue
– sequence: 8
  givenname: Shiqi
  surname: Lin
  fullname: Lin, Shiqi
– sequence: 9
  givenname: ChengAn
  surname: Liu
  fullname: Liu, ChengAn
– sequence: 10
  givenname: Han-Ping
  surname: Shi
  fullname: Shi, Han-Ping
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40133874$$D View this record in MEDLINE/PubMed
BookMark eNptk9tu1DAQhiNURA_wAlwgS0gIJFJs52CHG1StOKxUgVTg2po4zq5LEm9tp7TvwQMz2S1lg5AlH8bf_LbHM8fJweAGkyRPGT1lTJZvAuNSFinlRcqyilUpe5AcsVywlOdUHOzND5PjEC4pZUJS-Sg5zCnLMinyo-TX58UFgUCA1Nb14H8YT1rnyTBGb6N1A3QkRIgjIkND7NB20Pcw7eCCbLxprI52WBE3Ru16E7ZmBMwQA_lp45poGDTKatBrc2PhLR628S5sDDpem9ekH7toNfIIhTg2t4-Thy10wTy5G0-S7x_ef1t8Ss-_fFwuzs5TXUge0zpnjdAMGm6o1hzKLBdUS8hLoLytTEN13dai1pkWmpuaV5yCrnldMFYYSrOTZLnTbRxcqo23GIBb5cCqrcH5lQKPV-uMmgJW0spUlcxRv4VaMFEWUvNCs9o0qPVup7UZ694003M8dDPR-c5g12rlrhVjVZaXskKFl3cK3l2NJkTV26BN18Fg3BhUxiTLSknphD7_B710o8e_2lKiyCsh5V9qBfgC_DqHB-tJVJ3JjBeI5Qyp0_9Q2BrTW40Z11q0zxxezRyQieYmrmAMQS2_XszZF3vs2kAX18F145Q_YQ4-2w_ffdz-ZCoCfAdoTJ3gTXuPMKqmclC7clBYDmpbDtj_BgXR_K0
Cites_doi 10.1016/j.immuni.2019.06.025
10.1038/sj.bjc.6605578
10.1038/nature07205
10.1002/jcsm.12761
10.1186/1475-2891-11-27
10.1016/j.clnu.2016.09.004
10.1002/jcsm.13358
10.1016/S1470-2045(14)70263-3
10.1016/j.clnu.2019.12.024
10.3390/diagnostics13010116
10.1038/nrdp.2017.105
10.1016/j.esmoop.2021.100092
10.1016/S1470-2045(10)70218-7
10.1054/bjoc.2001.2046
10.1016/j.clnu.2017.06.017
10.1186/s13045-023-01454-0
10.1186/s12885-023-11590-y
10.1016/j.clnu.2022.04.019
10.1016/j.tem.2012.10.006
10.1016/j.clnu.2020.10.050
10.1002/jcsm.12528
10.1200/JCO.2008.18.9068
10.1093/ajcn/83.6.1345
10.1097/PN1099.0000000000000008
10.1200/JCO.2012.45.2722
10.1093/annonc/mdy004
10.1002/jpen.2407
10.1016/S0149-2918(05)80001-3
10.1038/ni.3754
10.1038/s41571-023-00734-5
ContentType Journal Article
Copyright 2025. The Author(s).
COPYRIGHT 2025 BioMed Central Ltd.
2025. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2025 2025
Copyright_xml – notice: 2025. The Author(s).
– notice: COPYRIGHT 2025 BioMed Central Ltd.
– notice: 2025. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2025 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12885-025-13919-1
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Acceso a contenido Full Text - Doaj
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Publicly Available Content Database





Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2407
EndPage 11
ExternalDocumentID oai_doaj_org_article_0133609e998446afab717658c25c1bed
PMC11934689
A832554941
40133874
10_1186_s12885_025_13919_1
Genre Multicenter Study
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: National Key Research and Development Program
  grantid: No. 2022YFC2009600
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ISR
ITC
KQ8
LGEZI
LOTEE
M1P
M48
M~E
NADUK
NXXTH
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c582t-b41d7c1ad2e0cc2a63470c8a46a02f9ed0cbfb7bc3c7c2eb2920acb2b5115e003
IEDL.DBID M48
ISSN 1471-2407
IngestDate Wed Aug 27 01:27:28 EDT 2025
Thu Aug 21 18:39:58 EDT 2025
Fri Jul 11 18:57:24 EDT 2025
Fri Jul 25 21:02:05 EDT 2025
Tue Jun 17 21:58:35 EDT 2025
Tue Jun 10 20:59:14 EDT 2025
Fri Jun 27 05:13:02 EDT 2025
Thu May 22 21:23:35 EDT 2025
Thu May 22 05:05:16 EDT 2025
Tue Jul 01 05:20:27 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Cancer cachexia
Malnutrition
NCR
Overall survival
Systemic inflammation
Language English
License 2025. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c582t-b41d7c1ad2e0cc2a63470c8a46a02f9ed0cbfb7bc3c7c2eb2920acb2b5115e003
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/3187549788?pq-origsite=%requestingapplication%
PMID 40133874
PQID 3187549788
PQPubID 44074
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_0133609e998446afab717658c25c1bed
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11934689
proquest_miscellaneous_3181368009
proquest_journals_3187549788
gale_infotracmisc_A832554941
gale_infotracacademiconefile_A832554941
gale_incontextgauss_ISR_A832554941
gale_healthsolutions_A832554941
pubmed_primary_40133874
crossref_primary_10_1186_s12885_025_13919_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-03-25
PublicationDateYYYYMMDD 2025-03-25
PublicationDate_xml – month: 03
  year: 2025
  text: 2025-03-25
  day: 25
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC cancer
PublicationTitleAlternate BMC Cancer
PublicationYear 2025
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References 13919_CR4
CG Lis (13919_CR31) 2012; 11
K Nordin (13919_CR16) 2001; 85
13919_CR2
RD Dolan (13919_CR30) 2020; 39
X Zhang (13919_CR22) 2023; 47
FR Greten (13919_CR17) 2019; 51
WD Dewys (13919_CR10) 1980; 69
L Martin (13919_CR11) 2013; 31
13919_CR32
KC Fearon (13919_CR29) 2006; 83
13919_CR14
T Cederholm (13919_CR24) 2017; 36
T Setiawan (13919_CR6) 2023; 16
JM Argiles (13919_CR3) 2023; 20
J Arends (13919_CR25) 2017; 36
BL Pierce (13919_CR21) 2009; 27
L Han (13919_CR5) 2024; 3
Q Zhang (13919_CR7) 2021; 12
GS de Castro (13919_CR20) 2021; 40
HL Xie (13919_CR12) 2021; 11
GT Ruan (13919_CR9) 2023; 14
M Tsoli (13919_CR26) 2013; 24
L Zitvogel (13919_CR27) 2017; 18
K Fearon (13919_CR1) 2011; 12
E Dell'Aquila (13919_CR15) 2018; 29
A Mantovani (13919_CR18) 2008; 454
13919_CR28
SI Go (13919_CR13) 2023; 23
M Pressoir (13919_CR23) 2010; 102
H Xie (13919_CR8) 2022; 41
CI Diakos (13919_CR19) 2014; 15
References_xml – volume: 51
  start-page: 27
  issue: 1
  year: 2019
  ident: 13919_CR17
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.06.025
– volume: 102
  start-page: 966
  issue: 6
  year: 2010
  ident: 13919_CR23
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6605578
– volume: 454
  start-page: 436
  issue: 7203
  year: 2008
  ident: 13919_CR18
  publication-title: Nature
  doi: 10.1038/nature07205
– volume: 12
  start-page: 1466
  issue: 6
  year: 2021
  ident: 13919_CR7
  publication-title: J Cachexia Sarcopenia Muscle
  doi: 10.1002/jcsm.12761
– volume: 11
  start-page: 27
  year: 2012
  ident: 13919_CR31
  publication-title: Nutr J
  doi: 10.1186/1475-2891-11-27
– volume: 36
  start-page: 49
  issue: 1
  year: 2017
  ident: 13919_CR24
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2016.09.004
– volume: 14
  start-page: 2813
  issue: 6
  year: 2023
  ident: 13919_CR9
  publication-title: J Cachexia Sarcopenia Muscle
  doi: 10.1002/jcsm.13358
– volume: 15
  start-page: e493
  issue: 11
  year: 2014
  ident: 13919_CR19
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70263-3
– volume: 39
  start-page: 2889
  issue: 9
  year: 2020
  ident: 13919_CR30
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2019.12.024
– ident: 13919_CR14
  doi: 10.3390/diagnostics13010116
– ident: 13919_CR2
  doi: 10.1038/nrdp.2017.105
– ident: 13919_CR28
  doi: 10.1016/j.esmoop.2021.100092
– volume: 3
  issue: 1
  year: 2024
  ident: 13919_CR5
  publication-title: Precision Nutrition
– volume: 12
  start-page: 489
  issue: 5
  year: 2011
  ident: 13919_CR1
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70218-7
– volume: 85
  start-page: 1265
  issue: 9
  year: 2001
  ident: 13919_CR16
  publication-title: Br J Cancer
  doi: 10.1054/bjoc.2001.2046
– volume: 36
  start-page: 1187
  issue: 5
  year: 2017
  ident: 13919_CR25
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2017.06.017
– volume: 16
  start-page: 54
  issue: 1
  year: 2023
  ident: 13919_CR6
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-023-01454-0
– volume: 23
  start-page: 1071
  issue: 1
  year: 2023
  ident: 13919_CR13
  publication-title: BMC Cancer
  doi: 10.1186/s12885-023-11590-y
– volume: 41
  start-page: 1236
  issue: 6
  year: 2022
  ident: 13919_CR8
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2022.04.019
– volume: 24
  start-page: 174
  issue: 4
  year: 2013
  ident: 13919_CR26
  publication-title: Trends Endocrinol Metab
  doi: 10.1016/j.tem.2012.10.006
– volume: 40
  start-page: 2443
  issue: 4
  year: 2021
  ident: 13919_CR20
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2020.10.050
– ident: 13919_CR32
  doi: 10.1002/jcsm.12528
– volume: 27
  start-page: 3437
  issue: 21
  year: 2009
  ident: 13919_CR21
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.18.9068
– volume: 83
  start-page: 1345
  issue: 6
  year: 2006
  ident: 13919_CR29
  publication-title: Am J Clin Nutr.
  doi: 10.1093/ajcn/83.6.1345
– ident: 13919_CR4
  doi: 10.1097/PN1099.0000000000000008
– volume: 31
  start-page: 1539
  issue: 12
  year: 2013
  ident: 13919_CR11
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.45.2722
– volume: 29
  start-page: 924
  issue: 4
  year: 2018
  ident: 13919_CR15
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdy004
– volume: 47
  start-page: 109
  issue: 1
  year: 2023
  ident: 13919_CR22
  publication-title: JPEN J Parenter Enteral Nutr
  doi: 10.1002/jpen.2407
– volume: 69
  start-page: 491
  issue: 4
  year: 1980
  ident: 13919_CR10
  publication-title: Am J Med
  doi: 10.1016/S0149-2918(05)80001-3
– volume: 18
  start-page: 843
  issue: 8
  year: 2017
  ident: 13919_CR27
  publication-title: Nat Immunol
  doi: 10.1038/ni.3754
– volume: 20
  start-page: 250
  issue: 4
  year: 2023
  ident: 13919_CR3
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-023-00734-5
– volume: 11
  year: 2021
  ident: 13919_CR12
  publication-title: Front Oncol
SSID ssj0017808
Score 2.4434352
Snippet Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate the...
Background Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate...
BackgroundSystemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to evaluate...
Abstract Background Systemic inflammation and nutritional status are key factors affecting the prognosis of patients with cancer cachexia. This study aims to...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 539
SubjectTerms Aged
Albumin
Analysis
Biological markers
Biomarkers
Biomarkers - blood
Blood
Body Mass Index
Breast
C-Reactive Protein - analysis
C-Reactive Protein - metabolism
Cachexia
Cachexia - blood
Cachexia - diagnosis
Cachexia - etiology
Cachexia - mortality
Cancer
Cancer cachexia
Cancer patients
Cancer therapies
Care and treatment
Cervical cancer
China - epidemiology
Constipation
Cytokines
Development and progression
Diagnosis
Diarrhea
Dyspnea
Female
Global health
Humans
Inflammation
Inflammation - blood
Insomnia
Liver
Lung cancer
Lymphocytes
Male
Malnutrition
Medical diagnosis
Medical prognosis
Middle Aged
Mortality
Musculoskeletal system
NCR
Neoplasms - complications
Neoplasms - mortality
Nutritional Status
Oncology, Experimental
Overall survival
Patient outcomes
Patients
Prognosis
Prospective Studies
Proteins
Quality of life
Questionnaires
Risk factors
Survival analysis
Systemic inflammation
Tumor necrosis factor-TNF
SummonAdditionalLinks – databaseName: Acceso a contenido Full Text - Doaj
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gL4ptAAYOQOEBUx_mww61UVAWpPRQq9WbZjgO9ZKvNRuKH9Af3jZOsNuLAhdNq48kmmXkev9nMjBl7D5dfVUWJMLV2bVq4RqVO2Ta1IletrV0WBBU4n55VJxfF98vycmerL8oJG9sDj4o7AEXJK1EHhAWIXGxrHQIQLJtelj5zoSHvizVvDqam9wdKCz2XyOjqoIcX1lSJXKZgPFmdZotlKHbr_9sn7yxKy4TJnRXo-AG7P1FHfjje8kN2J3SP2N3T6eX4Y3ZzdnTObc8tp5p6SrtZc1BS3s0N93Ey1Q8NEOkaDmgBDWPlIr7w6zX9EmVB89WwARBDHw-PjVd7Tv_Yck8gWeMDtv5zZT_jYniOuVzzE4_5iXT_EIqda5-wi-OvP49O0mnThdSXWm5SV2SN8pltZBDeS1vlhRJeW-heyLYOjfCudcr53CsvEZfXUljvpANzKwN8xFO216268JxxDfMHhC-gXLLQVlvQhdbpzOdKtFLVCfs428Bcj701TIxJdGVGixlYzESLmSxhX8hMW0nqix0PAC1mQov5F1oS9oaMbMYi0-3sNodwbCBWdYHLvIsS1Bujo-SbX3boe_Ptx_lC6MMk1K4ACCh9rGXAc1M7rYXk_kISk9cvh2e0mcl59AZuVpW0859O2NvtMJ1JCXFdWA1RJssrsH1o8dkIzq1mKGTOtSoSphewXahuOdJd_Y6txTPw-aLS9Yv_oeyX7J6kKSfyVJb7bG-zHsIrULiNex1n6y0B6kR-
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4t2FAgYhcYCojvOwwwWViqogtYdCpd4s23FKL8my2ZX4IfxgvnGSpRESp1XiySaZl79xZsaMvYHLL8u8QJhauSbJXa0Sp2yTWJGpxlYuDYIKnE9Oy-Pz_OtFcTEuuPVjWuXkE6OjrjtPa-T70D1V0HZo-uPyZ0K7RtHX1XELjZvsFrUuo5QudbENuFKlhZ4KZXS538MXa6pHLhLgnrRK0tlkFHv2_-uZr01N87TJa_PQ0T12dwSQ_GCQ-H12I7QP2O2T8RP5Q_b79PCM255bTpX1lHyz4gCmvJ3a7uNiqiLagKStORQMOjHUL-KAL1f0T5QLzbvNGqwJfTw9tF_tOa3bck-qssIPJP7ryn7AzfAeU9Hmex6zFOn5QRT71z5i50efvx8eJ-PWC4kvtFwnLk9r5VNbyyC8l7bMciW8tnlphWyqUAvvGqecz7zyEtF5JYX1TjrgtyLAUzxmO23Xhl3GNZQgIIgB8JK5ttoCNDROpz5TopGqWrB3kwzMcuiwYWJkokszSMxAYiZKzKQL9onEtKWk7tjxRLe6NKOxGcDarBRVQCiJaNc21iFoBdTysvCpC_WCvSQhm6HUdGvj5gDuDfCqynGb15GCOmS0lIJzaTd9b758O5sRvR2Jmg4KAaYPFQ14b2qqNaPcm1HChP18eNI2M7qQ3vxV-AV7tR2mKyktrg3dJtKkWQnMDy4-GZRzyxkKnDOt8gXTM7WdsW4-0l79iA3GYUtZXurq6f-f6xm7I8mYRJbIYo_trFeb8BwQbe1eRDv8A7R0PME
  priority: 102
  providerName: ProQuest
Title NCR as a biomarker for nutritional status and inflammation in predicting outcomes in patients with cancer cachexia: a prospective, multicenter study
URI https://www.ncbi.nlm.nih.gov/pubmed/40133874
https://www.proquest.com/docview/3187549788
https://www.proquest.com/docview/3181368009
https://pubmed.ncbi.nlm.nih.gov/PMC11934689
https://doaj.org/article/0133609e998446afab717658c25c1bed
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLbGJiFeEHcKoxiExAMEEudiBwmhddo0kFqhQqWKF8t2nDEJpSNppfE_-MF8dpKyiD3w0qrxSdycm8-XnHNMyAu4_CxLUsDUXJdBogseaK7KQIUxL1WuIxu6AufpLDtZJJ-W6XKH9NsddQxsroR2bj-pRf3jzcXPXx9g8O-9wYvsbQMfK1ydcRognonyAGhoDysTd4Y6Tf6-VeDC71AXwSG7twq8L6K58hqDhcr38__Xa19atoYplZfWqONb5GYXXNKDVhtukx1b3SHXp93r87vk9-xwTlVDFXVV9y4xp6YIWmnVt-THya7CaAOSqqBgB_SlrW3ED3peuyu5PGm62qyhqrbxh9vWrA11z3SpcWpU4wvacHGm3mEy3Edf0Pma-gxG9_9B5Hvb3iOL46OvhydBty1DYFLB1oFOooKbSBXMhsYwlcUJD41QSaZCVua2CI0uNdcmNtwwIPechcpophHbpRZe5D7ZrVaVfUiogIJYABwEZSwRSigEFKUWkYl5WDKej8irXgbyvO2-IT1qEZlsJSYhMeklJqMRmTgxbSld52x_YFWfys4QJULeOAtzC5gJJKxKpQFoEYYZlppI22JEnjohy7YMdWv_8gCuD6FXnmCa557Cdc-oXHrOqdo0jfz4ZT4getkRlSsoBJjeVjvgvl3DrQHl_oAS5m2Gw722yd46JBwxT93egGJEnm2H3ZkuZa6yq42nieIMeABcfNAq55YzDlTHgicjIgZqO2DdcKQ6--6bj0eI-JNM5I_-Y-LH5AZzFhXGAUv3ye663tgniOHWekyu8SUfk73J0ezzfOyfhIy9seJzPvn2B5ZGSDE
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbKVgIuiH8WCjUIxIFGTRwndpAQakurXdpdodJKvRnbcUovybLZFfAePAfPyIyTLI2QuPW02njy5_k8ni-eGRPyEkx-mvIEaGpmioCbXARG6CLQYSwKnZnIhZjgPJmmo1P-8Sw5WyO_u1wYDKvsbKI31Hll8Rv5NmBPJLgdmnw_-xbgrlG4utptodHA4tD9_A6UrX43_gD6fcXYwf7J3ihodxUIbCLZIjA8yoWNdM5caC3TacxFaKXmqQ5Zkbk8tKYwwtjYCsuAeGYs1NYwA65J4mAQwHWvkXUeA5UZkPXd_emn49W6hZCh7FJzZLpdg_WXmAGdBOBpRVkQ9aY_v0vAv3PBpcmwH6h5aeY7uE1utS4r3WkwdoesufIuuT5pF-XvkV_TvWOqa6op5vJjuM-cgitMy67QP5yMeUtLEClzCpAGFDYZk_CHzuZ4JYy-ptVyAcpwtT_cFHytKX4pphbBOYcfwNiPC_0Wbgbv0aWJblEfF4nPD0K-Yu59cnolanlABmVVukeESoCdA9oErh7jUksNbkphZGRjERZMZEPyptOBmjU1PZTnQjJVjcYUaEx5jaloSHZRTStJrMftD1Tzc9UObwWONOAhc0BegV_rQhugyeDcWZbYyLh8SDZRyapJbl1ZFbUDBhUcuozDbV54CazJUWLQz7le1rUafz7uCb1uhYoKAAGd3uRQwHtjGa-e5EZPEoyG7Td3aFOt0arV3yE2JM9XzXgmBuKVrlp6mShOgWVALz5swLnqGaTqsRR8SGQPtr2u67eUF199SfMIeARPZfb4_8-1SW6MTiZH6mg8PXxCbjIcWGEcsGSDDBbzpXsKDuLCPGtHJSVfrtoQ_AHP63yW
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=NCR+as+a+biomarker+for+nutritional+status+and+inflammation+in+predicting+outcomes+in+patients+with+cancer+cachexia%3A+a+prospective%2C+multicenter+study&rft.jtitle=BMC+cancer&rft.au=Li%2C+Xiangrui&rft.au=Deng%2C+Li&rft.au=Xie%2C+Hailun&rft.au=Li%2C+Shuqun&rft.date=2025-03-25&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=25&rft.issue=1&rft.spage=539&rft_id=info:doi/10.1186%2Fs12885-025-13919-1&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon